• Skip to main content
  • Skip to primary sidebar
  • Home
  • Events
  • Videos
  • About Us
  • Contact Us

CancerCode.org

Worldwide Cancer Incidence Predicted to Rise 75% by 2030

THURSDAY, May 31 (HealthDay News) — The worldwide incidence of
cancer is expected to increase 75 percent by 2030, with a projected
increase of more than 90 percent in the poorest nations, a new study
reveals.

Rates of certain types of cancer (such as cervical and stomach cancer)
appear to be declining in some developing countries, but these reductions
are likely to be offset by substantial increases in the types of cancer
associated with a “westernized” lifestyle, including breast, prostate and
colorectal cancer, according to the report published online May 31 in
The Lancet Oncology.

For the study, researchers analyzed International Agency for Research
on Cancer (IARC) data from 184 countries in 2008 in order to examine how
current and future cancer trends vary between countries based on their
levels of development, as measured by their Human Development Index
(HDI).

Currently, countries with a low HDI (mainly nations in sub-Saharan
Africa) have a high incidence of cancers associated with infection
(particularly cervical cancer), as well as liver cancer, stomach cancer
and Kaposi’s sarcoma. Countries with a higher HDI (such as Australia,
Brazil, Russia and the United Kingdom) have higher rates of cancers
associated with smoking (lung cancer), reproductive risk factors, obesity
and diet (breast, prostate and colorectal cancer).

Improved living standards in countries with a lower HDI may lead to a
decrease in some infection-related cancers, but these countries may see a
sharp increase in the types of cancer currently seen in higher-development
countries, the researchers pointed out in a journal news release.

Cancer incidence rates could increase by 93 percent in low HDI
countries by 2030, and by 78 percent in medium HDI countries (such as
South Africa, China and India) over the same period, according to study
leader Dr. Freddie Bray, of IARC, and colleagues.

The investigators also found that rates of prostate cancer and female
breast cancer appear to be rising in most countries with medium, high or
very high levels of development, and that rates of stomach cancer and
cervical cancer are generally decreasing in countries with medium, high or
very high levels of HDI.

Lung cancer is currently not a leading type of cancer in low HDI
countries, but that will change unless smoking is effectively controlled
in these countries, the study authors noted in the news release.

The researchers also found that 40 percent of worldwide cancer cases in
2008 occurred in countries with very high HDI levels, even though they had
just 15 percent of the global population.

More information

The World Health Organization has more about cancer.

Ben Foster

West Clinic Welcomes Daruka Mahadevan, MD, PhD New Director of Phase I Clinical Trials Program and Associate Director of Research


 

MEMPHIS, Tenn., May 31, 2012 /PRNewswire-USNewswire/ — The West Clinic, the Mid-South’s premier cancer center and world-class center of excellence in medical oncology, hematology, oncologic imaging, clinical research and other advanced medical care, announced today the addition of Daruka Mahadevan, MD, PhD, preeminent cancer scientist, to its internationally-renowned research team. Dr. Mahadevan is the former Associate Professor of Medicine and Director of the Phase I, New Drug Program Development at the University of Arizona-Arizona Cancer Center. He is being named Director of the Phase One Clinical Trials Program and Associate Director of Research with The West Clinic and Full Professor with the Division of Hematology Oncology at the University of Tennessee Health Science Center (UTHSC).

Noted internationally for his accomplishments in building the Phase I Program at the University of Arizona, Dr. Mahadevan’s major area of clinical research interest is in the treatment and management of patients with Pancreatic cancer, Gastrointestinal Stromal Tumors (GIST), Myelodysplastic Syndromes (MDS) and non-Hodgkin’s lymphoma (NHL) including Chronic Lymphocytic Leukemia (CLL). As Director of the Phase I Program, he will conduct first-in-human clinical trials with novel drugs for patients with all solid tumor types as well as patients with MDS, CLL and NHL.

“We are pleased to welcome Dr. Mahadevan to the UTHSC faculty,” said David M. Stern, M.D., executive dean of the College of Medicine and vice chancellor of Clinical Affairs for the University of Tennessee Health Science Center.  “His proven expertise, professionalism and commitment to scientific discovery will enhance the extant talents and amplify the educational offerings within our institution.”

DEVELOPING A WORLD-CLASS PHASE I RESEARCH PROGRAM WITH DR. MAHADEVAN

According to Lee S. Schwartzberg, MD, Medical Director, The West Clinic; Chief, Division of Hematology/Oncology and Professor of Medicine, University of Tennessee Health Science Center, and President, ACORN Research, “The West Clinic has been building our clinical research program for many years and we are focused on expanding our Phase 1 capabilities. We are extremely excited to recruit Dr. Mahadevan as Director of our Phase I Program.  He brings a wealth of experience and academic rigor as an experienced scientist to our efforts. He organized the Phase I Program at the University of Arizona and will further develop our Phase I Program and research capabilities to new heights, allowing us to offer the most comprehensive clinical trials program in the region. This will enhance our capabilities to compete with any center in the United States.”

“Dr. Mahadevan is the first translational scientist to join The West Clinic,” Schwartzberg continued. “He brings a lab in drug discovery with grants recognized by the NCI with distinction worthy of funding. Dr. Mahadevan will play a pivotal role as a foundational scientist to bring our cancer center with Methodist Healthcare and University of Tennessee Health Science Center to fruition.”

“This is exactly the caliber of talent we envisioned attracting to The West Clinic, when we announced our partnership last year,” said Gary S. Shorb, President and CEO, Methodist Le Bonheur Healthcare.  “The West Clinic, the University of Tennessee Health Science Center and Methodist are proud to be able to enhance cancer research for our patients.”

ABOUT DR. MAHADEVAN

Daruka Mahadevan, M.D., Ph. D., is former Associate Professor of Medicine and Director of the Phase I, New Drug Development Program at the University of Arizona – Arizona Cancer Center.  He received his B.Sc. (Hons.) in Physiology and Biochemistry with Chemistry from the University of Reading, England, Ph.D. in protein crystallography from Birkbeck College, University of London and medical degree from King’s College Hospital Medical School, University of London, England, United Kingdom. Dr. Mahadevan completed a post-doctoral Fogarty International fellowship at the National Cancer Institute/NIH and was a senior research scientist at Celltech Therapeutics, London, England. He completed internal medicine residency at University of Connecticut and fellowship training in Hematology/Oncology at the AZCC. He is certified by the American Board of Internal Medicine and Medical Oncology. He has written over 70 peer-reviewed full length articles included in Nature, Blood and the Journal of Clinical Oncology, several book chapters and six US patents on novel agents targeting cancer.

“I am excited to be joining The West Clinic and build a world-class Phase I program of translational research with the University of Tennessee and build a collaboration with ACORN Research,” stated Dr. Mahadevan. ” My vision is to be able to keep patients alive for at least a year beyond their final standard of care. This will be a great service to patients in our care. In addition, this will be a great research opportunity to learn from this experience and to build new molecules into frontline cancer therapies.”

“ACORN Research is very excited to welcome Dr. Mahadevan to The West Clinic as he will add significant scientific bandwidth to the types of projects we can support.  Combining academic expertise with the robust private sector research capabilities found at ACORN Research creates powerful synergy to fuel research productivity in oncology,” observed Edward Stepanski, Ph.D., Chief Operating Officer at ACORN Research LLC.

About The West Clinic

The West Clinic has been the Mid-South’s premier provider of cancer care for over 33 years. With a team second to none in breadth of expertise, dedication to excellence, and compassionate care, our multidisciplinary physician group is comprised of 30 specialists in Medical Oncology, Hematology, Gynecologic Oncology, Breast Surgery, Endocrinology, Diagnostic and Interventional Radiology, Pain and Palliative Care, and other advanced medical care. With eight locations in Memphis, West TN, and North MS, patients across the Mid-South have greater access to the highest quality care available.

The West Clinic’s clinical research program, under the direction of Lee S. Schwartzberg, MD, FACP, Medical Director, is internationally renowned. Over the past two decades, West Clinic has consistently been one of the first centers in the US to gain experience and hasten the development of new drugs for breast cancer, colon cancer, lung cancer, prostate cancer, lymphoma, and many other diseases.

In 2012, The West Clinic formed a partnership with Methodist Healthcare and the University of Tennessee Health Science Center (UTHSC) in order to transform cancer care in the Mid-South. This novel partnership takes advantage of the strengths and culture of all three partners that are leading to the development of a fully integrated cancer program which will expand our collaborative efforts in cancer research and education along with a vision toward personalized precision cancer care.

About ACORN Research, LLC

ACORN Research, LLC is a multifaceted research organization that harmonizes a network of committed oncology research sites supported by centralized research processes, a bioinformatics platform that integrates EMR data with ePRO data to support health outcomes research and clinical trial efficiencies, and a Contract Research Organization focused exclusively on oncology. AdeptBio, LLC, an ACORN partnership, offers high quality biospecimens and biofluids using unmatched sophistication in donor services.

CONTACT: [Read more…] about West Clinic Welcomes Daruka Mahadevan, MD, PhD New Director of Phase I Clinical Trials Program and Associate Director of Research

Ben Foster

Zyngenia, Inc. Appoints Frank Hsu, M.D., as Chief Medical Officer


 

GAITHERSBURG, Md., May 31, 2012 /PRNewswire/ — Zyngenia, Inc., a biopharmaceutical company developing Zybodies (next-generation multi-specific antibody-based drugs) in oncology and immunology, announced today that it has appointed Frank Hsu, M.D., as Chief Medical Officer (CMO) and a member of its executive team. Dr. Hsu is a medical oncologist and immunologist with deep academic and industry clinical research experience who most recently served as Senior Medical Director at Genzyme.

“Since our start in September 2009, we at Zyngenia have validated our technology platform, developed a suite of novel multi-specific biological drug candidates, and built a world-class drug discovery and development team,” said Zyngenia President and CEO Peter A. Kiener, D.Phil. “As we move our lead programs into clinical testing, we are very fortunate to be able to bring on Dr. Hsu, an accomplished researcher and drug developer. Frank brings tremendous expertise to Zyngenia from his leadership role at Genzyme where he supervised clinical development activities of early- and late-stage products such as GC1008, Campath® and Thymoglobulin®, and helped lead the successful development and global drug registrations of Mozobil®. The recent additions of both Frank Hsu and David Parkinson, who will continue to serve as chairman of our clinical advisory board and as a member of our board of directors, have added industry-leading clinical and strategic depth to the Zyngenia leadership team.”

“I am very pleased to join Zyngenia as the company moves drug candidates into clinical trials,” said Dr. Hsu. “The company is at a very exciting stage as it is poised to demonstrate that targeting multiple disease pathways simultaneously with an antibody-like drug may have major impact on treating diseases where there are significant unmet medical needs. I believe that Zyngenia is ready to make very significant contributions to developing more effective therapies in oncology and autoimmune diseases.”

About Frank Hsu, M.D.

Prior to joining Zyngenia, Dr. Hsu was Senior Medical Director at Genzyme in the Transplant and Oncology Division.  For over nine years, he was responsible for the clinical development of products in the areas of hematology, oncology and stem cell transplant.  In addition to his support of commercial products, he oversaw early clinical development of investigational agents including antibodies and vaccines and led the development of biomarker/early endpoint analyses and initial patient studies. He also actively provided medical support related to business development, strategic planning, partnership management, medical affairs, and corporate acquisitions.

Dr. Hsu received his undergraduate degree from Stanford University and his medical degree from Harvard Medical School as part of the Health, Science and Technology (Harvard-MIT) program.  His residency training in Internal Medicine was at the University of California, San Francisco.  He then spent six years as a clinical and research fellow in Oncology at Stanford University.  Dr. Hsu joined the faculty of Yale University in 1996 and served as an Assistant Professor of Medicine in the Section of Oncology and as co-Director of the Immunology Research Program of the Yale Cancer Center until 2003.

During his academic career, Dr. Hsu’s research focused on non-Hodgkin’s lymphomas, Hodgkin’s disease and multiple myeloma.  His work involved both basic immunology and translational efforts to develop novel anti-cancer antibodies and idiotype vaccines for the treatment of B cell non-Hodgkin’s lymphomas and included the first clinical trial of an anti-cancer vaccine based on antigen-pulsed dendritic cells. He was a recipient of several awards including the James S. McDonnell Fellow Award for Molecular Medicine in Cancer Research and was a translational research fellow of the Leukemia and Lymphoma Society. Dr. Hsu also serves on the Board of Trustees of the Grunebaum Cancer Research Foundation.

About Zyngenia, Inc.

Zyngenia, Inc. is a privately held biotherapeutics company focused on the development of next-generation multi-specific antibody-based therapeutics. The company uses proprietary patented technology to engineer single molecular entities that interact with two or more targets. The multiple target strategy has created many opportunities for innovative therapeutics with new mechanisms of action that are not achievable with single specificity antibodies. The company has initially focused its Zybody™ development on therapies for various cancers and autoimmune disorders. Zyngenia, whose lead investor is New Enterprise Associates, is headquartered in Gaithersburg, Maryland. For more information, visit www.zyngenia.com.

* Campath®, Thymoglobulin®, and Mozobil® are registered trademarks of Genzyme Corporation.

SOURCE Zyngenia, Inc.

Back to top
RELATED LINKS [Read more…] about Zyngenia, Inc. Appoints Frank Hsu, M.D., as Chief Medical Officer

Ben Foster

No Disparities Found In Imaging Before Breast Cancer Surgery



No Disparities Found In Imaging Before Breast Cancer Surgery (via redOrbit)

Survival differences between black and white women having breast cancer do not stem from differences in preoperative imaging If racial and ethnic disparities in breast cancer exist, they are not due to differences in the use of imaging to assess the extent of tumors before surgery, according to new…

[Read more…] about No Disparities Found In Imaging Before Breast Cancer Surgery

Ben Foster

Weight Loss: Separating Fact from Fiction



Weight Loss: Separating Fact from Fiction (via PR Newswire)

LOS ANGELES, May 23, 2012 /PRNewswire/ — ABC’s “20/20” recently aired a special, entitled “Losing It: The Big Fat Money Pit,” that examined the burgeoning weight loss industry as a whole. Many of the methods discussed – from dieting to pills and surgery – have been popularized by celebrities who…

[Read more…] about Weight Loss: Separating Fact from Fiction

Ben Foster

Five Secret Habits of Successful Weight Loss!



Five Secret Habits of Successful Weight Loss! Clip this story (via http://ihealthy.myiamrich.com)

Quote: ‘In eating, a third of the stomach should be filled with food, a third with drink and the rest left empty. ’ Talmudin Hello! May I start this article by sharing with you my most inner secrets. I want to reveal to you that no matter how difficult your weight problem may seem, you can change…

[Read more…] about Five Secret Habits of Successful Weight Loss!

Ben Foster

Texas Children’s Fetal Center First in Southwestern United States to Perform Experimental In-Utero Procedure to Treat Congenital Diaphragmatic Hernia Source: PR Newswire (http://s.tt/1cvMX)



Texas Children’s Fetal Center First in Southwestern United States to Perform Experimental In-Utero Procedure to Treat Congenital Diaphragmatic Hernia (via PR Newswire)

HOUSTON, May 22, 2012 /PRNewswire-USNewswire/ — As one of the country’s leading medical centers for diagnosing and treating fetal anomalies, and one of the first centers to provide a full range of prenatal surgical options, Texas Children’s Fetal Center at the Pavilion for Women is proud to announce…

[Read more…] about Texas Children’s Fetal Center First in Southwestern United States to Perform Experimental In-Utero Procedure to Treat Congenital Diaphragmatic Hernia Source: PR Newswire (http://s.tt/1cvMX)

Ben Foster

Children with Cancer Have Complete Responses in a Children’s Oncology Group Phase 1 Trial



Children with Cancer Have Complete Responses in a Children’s Oncology Group Phase 1 Trial (via PR Newswire)

PHILADELPHIA, May 16, 2012 /PRNewswire/ — A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma. To view the multimedia assets…

[Read more…] about Children with Cancer Have Complete Responses in a Children’s Oncology Group Phase 1 Trial

Ben Foster

Snoring Could Be Deadly



Snoring Could Be Deadly (via redOrbit)

Those with sleep apnea and a chronic snore may have an increased risk of cancer mortality, according to a new study to be presented at this year’s American Thoracic Society conference in San Francisco. The culprit is sleep disordered breathing (or SDB), and those with this condition also face an…

[Read more…] about Snoring Could Be Deadly

Ben Foster

Italian Baby Receives World’s Smallest Artificial Heart



Italian Baby Receives World’s Smallest Artificial Heart (via redOrbit)

Connie K. Ho for RedOrbit.com Italian doctors recently announced they completed an operation that implanted the smallest artificial heart in a 16-month-old baby boy. He received the device prior to obtaining a permanent organ donation. The operation was completed at Bambino Gesù Hospital, a children…

[Read more…] about Italian Baby Receives World’s Smallest Artificial Heart

Ben Foster

  • « Go to Previous Page
  • Go to page 1
  • Interim pages omitted …
  • Go to page 3
  • Go to page 4
  • Go to page 5
  • Go to page 6
  • Go to page 7
  • Interim pages omitted …
  • Go to page 10
  • Go to Next Page »

Primary Sidebar

Categories

Blog Archives

Copyright © 2021 www.CancerCode.org